Semaglutide is a GLP-1 receptor agonist that mimics an incretin hormone to improve glycemic control, reduce appetite, and slow gastric emptying. Its healthspan relevance stems from its profound ability to induce weight loss and resolve metabolic dysfunction, two of the most significant drivers of age-related chronic disease.
Verdict
A powerful tool for metabolic health, but requires careful medical management.
HEALTHSPAN IMPACT
High Value
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$1000 - $1600
Protocol
- Weekly subcutaneous injections starting at 0.25 mg, titrating up based on tolerance and goals.
- Daily oral tablets (Rybelsus) starting at 3 mg, titrating up as directed.
- Lower maintenance doses may be used for metabolic health benefits without aggressive weight loss.
Flags
- Requires a prescription and ongoing medical supervision.
- Common side effects include nausea, vomiting, and diarrhea, especially during dose titration.
- Risk of muscle mass loss alongside fat loss; resistance training is crucial.
- Boxed warning for risk of thyroid C-cell tumors based on rodent studies.
- May interact with oral medications by delaying their absorption.
- Rare risks include pancreatitis, gallbladder problems, and gastroparesis.